DOCSLIB.ORG

Plasma Cell Leukaemia (PCL)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Plasma Cell Leukaemia (PCL) Plasma Cell Leukaemia (PCL) A Guide for Patients Introduction Being diagnosed with Plasma Cell Leukaemia (PCL) can be a shock, particularly when you may never have heard of it. If you have questions about PCL – what causes it, who it affects, how it affects your body, what symptoms to expect and likely treatments – this booklet covers the basics for you. For more information, talk to your ensures it is of the highest quality. haematologist, clinical nurse Unfortunately, due to the rarity of specialist or hospital pharmacist. PCL, we were unable to complete the production process which meant Booklet compiled by our Patient that this booklet cannot be formally Information Writer Isabelle Leach accredited. However, we assure you and peer reviewed by Dr Salim that this information was created Shafeek. with the same values as that which is. Disclaimer: As we are accredited by the Information Standard, all of our information has to adhere to a standardised process that If you would like any information on the sources used for this booklet, please email [email protected] for a list of references. Version 1 Printed: 06/2019 2 www.leukaemiacare.org.uk Review date: 06/2021 In this booklet Introduction 2 In this booklet 3 About Leukaemia Care 4 What is PCL? 6 Symptoms of PCL 10 Diagnosis of PCL 12 Prognosis of PCL 14 Treating PCL 16 Seeing your doctor 20 Telling your family 22 Managing your emotions 24 Survivorship 28 Palliative care 30 End of life care 32 Glossary 34 Useful contacts and further support 39 Helpline freephone 08088 010 444 3 About Leukaemia Care Leukaemia Care is a national charity dedicated to ensuring that people affected by blood cancer have access to the right information, advice and support. Our services has been affected by a blood cancer. A full list of titles – both Helpline disease specific and general Our helpline is available 8:30am information titles – can be – 5:30pm Monday - Friday and found on our website at www. 7:00pm – 10:00pm on Thursdays leukaemiacare.org.uk/support- and Fridays. If you need someone and-information/help-and- to talk to, call 08088 010 444. resources/information-booklets/ Alternatively, you can send Support Groups a message via WhatsApp on Our nationwide support groups 07500068065 on weekdays are a chance to meet and talk 9:00am – 5:30pm. to other people who are going Nurse service through a similar experience. For more information about a We have two trained nurses on support group local to your area, hand to answer your questions go to www.leukaemiacare.org. and offer advice and support, uk/support-and-information/ whether it be through emailing support-for-you/find-a-support- [email protected] or group/ over the phone on 08088 010 444. Buddy Support Patient Information Booklets We offer one-to-one phone We have a number of patient support with volunteers who have information booklets like had blood cancer themselves this available to anyone who or been affected by it in some 4 www.leukaemiacare.org.uk way. You can speak to someone Website who knows what you are going You can access up-to-date through. For more information information on our website, on how to get a buddy call www.leukaemiacare.org.uk. 08088 010 444 or email [email protected] Campaigning and Advocacy Online Forum Leukaemia Care is involved in campaigning for patient well- Our online forum, being, NHS funding and drug www.healthunlocked.com/ and treatment availability. If you leukaemia-care, is a place would like an update on any of for people to ask questions the work we are currently doing or anonymously or to join in the want to know how to get involved, discussion with other people in a email advocacy@leukaemiacare. similar situation. org.uk Patient and carer conferences Patient magazine Our nationwide conferences Our quarterly magazine includes provide an opportunity to inspirational patient and carer ask questions and listen to stories as well as informative patient speakers and medical articles by medical professionals: professionals who can provide www.leukaemiacare.org.uk/ valuable information and support. communication-preferences/ Helpline freephone 08088 010 444 5 What is PCL? Plasma cell leukaemia (PCL) is for 1% of previously diagnosed a rare and aggressive variant of multiple myeloma cases and is a multiple myeloma characterised more aggressive disease with a by a very high number of poorer prognosis. plasma cells in the blood and Plasma cells develop from bone marrow. The distinction B-lymphocytes that have been between multiple myeloma and activated, and they produce a plasma cell leukaemia is based single type of antibody which is on the presence of a circulating specific to a particular antigen, peripheral blood plasma cell for example the E coli bacteria. count of greater than 20% of white blood cells and/or more than Who is affected by 2x106/ml of leukaemic plasma cells in the peripheral blood. plasma cell leukaemia? Because PCL is such a rare Approximately 60 to 70% of PCL condition, information about its cases are new blood cancers at incidence, disease characteristics diagnosis, known as primary and treatment have mainly been PCL, while 30 to 40% occur as gathered retrospectively from secondary transformations of case reports or series of case multiple myeloma in patients reports. There have not been many with relapsed/refractory multiple prospective trials of patients with myeloma, when they are known as PCL. secondary PCL. Retrospective studies have Primary PCL is a distinct cancer provided most of the information with different molecular and that is known about PCL. This chromosomal findings than is where data from studies that secondary PCL and multiple have already been completed are myeloma. Primary PCL represents subsequently analysed to see 2 to 4% of myelomas. Multiple which treatments achieved the myeloma is a relatively best results for which patients. common cancer of plasma cells representing 10 to 15% of all blood A prospective trial is designed cancers. Secondary PCL accounts to determine a specific answer, 6 www.leukaemiacare.org.uk for example what are the disease a retrospective study of the characteristics of a condition, incidence of haematological or whether treatment A is cancers from cancer registries better than treatment B for the for the years 2000 to 2002, that condition. The study is conducted included 92 cases of PCL. in patients who meet particular Based on data from a series of inclusion criteria and following patient case reports, the median completion of the trial, the results age of patients with primary PCL are collected and analysed. Until at diagnosis is between 50 and recently, assessing treatments for 59 years. This is younger than for PCL using prospective studies was multiple myeloma patients where not possible as it was difficult the median age at diagnosis to recruit enough patients for is between 66 and 70 years, a trial with meaningful results. confirming that primary PCL is The largest prospective trial to a different condition to multiple date included 29 patients with myeloma. PCL is twice as common newly diagnosed primary PCL to in people of African descent investigate the efficacy of drug compared with Caucasians, and combinations which included it is slightly more common in bortezomib. See the treatment men than women (60% to 40%); section for more details about however, this data is based on this trial. case series. In a more recent The risk of suffering from PCL retrospective study of 50 patients is very low with an estimated with primary PCL, the male to incidence of 0.4 cases per female ratio was 50% to 50%. million individuals per year. Secondary PCL occurs after the This incidence is from a recent initial diagnosis of myeloma retrospective study of case and gradual genetic progression reports where 117 patients with and changes. This can be primary PCL were treated between during the natural history of the January 2006 and December myeloma progression through 2016. A similar incidence for various treatments and new PCL was previously found in mutations at various time Helpline freephone 08088 010 444 7 What is PCL? (cont.) points like a subsequent relapse. called an immunoglobulin, The likelihood for developing which is secreted by cancerous secondary PCL is very low at about plasma cells and can be 0.5 - 1%. There are no predictive detected in the blood and/or the factors or features towards urine of most myeloma patients. secondary PCL, but the average Multiple myeloma is age of diagnosis for secondary • classified depending on which PCL is 66 years old. immunoglobin antibody is What causes plasma identified. M-protein will cell leukaemia? normally be an immunoglobin G (IgG) or an immunoglobin A The causes of primary PCL are (IgA). Less commonly, IgD or IgE currently unclear. The control are seen. Secondary PCL occurs mechanisms that keep the more frequently in IgE and IgD plasma cells within the bone myelomas. marrow, rather than letting them enter the blood stream as in PCL, • These are areas of overlap are still unknown. between the secretory type of PCL and multiple myeloma. Primary PCL is a unique subgroup of the plasma cell myelomas, and In non-secretory type of PCL, no it displays a different biological M-protein is secreted. background and separate Immunophenotyping laboratory features. Despite having unique biological criteria, The immunophenotyping process some of the genetic markers may helps analyse the antibodies overlap with multiple myeloma. in patients based on the types of antigens or markers on the PCL has two types: secretory and surface of the cancer cells. non-secretory. According to which antibodies are In the secretory type of PCL, present, it is possible to identify M-protein is released.
Load more

Recommended publications
  • Plasma Cells: Finding New Light at the End of B Cell Development Kathryn L
    © 2001 Nature Publishing Group http://immunol.nature.com REVIEW Plasma cells: finding new light at the end of B cell development Kathryn L. Calame Plasma cells are cellular factories devoted entire- Upon plasma cell differentiation, there is a marked increase in ly to the manufacture and export of a single prod- steady-state amounts of Ig heavy and light chain mRNA and, when 2 uct: soluble immunoglobulin (Ig). As the final required for IgM and IgA secretion, J chain mRNA . Whether the increase in Ig mRNA is due to increased transcription, increased mediators of a humoral response, plasma cells mRNA stability or, as seems likely, both mechanisms, remains con- play a critical role in adaptive immunity.Although troversial2. There is also an increase in secreted versus membrane intense effort has been devoted to studying the forms of heavy chain mRNA, as determined by differential use of poly(A) sites that may involve the availability of one component of regulation and requirements for early B cell the polyadenylation machinery, cleavage-stimulation factor Cst-643. development, little information has been avail- To accommodate translation and secretion of the abundant Ig able on plasma cells. However, more recent mRNAs, plasma cells have an increased cytoplasmic to nuclear ratio work—including studies on genetically altered and prominent amounts of rough endoplasmic reticulum and secreto- ry vacuoles. mice and data from microarray analyses—has Numerous B cell–specific surface proteins are down-regulated begun to identify the regulatory cascades that upon plasma cell differentiation, including major histocompatibility initiate and maintain the plasma cell phenotype. complex (MHC) class II, B220, CD19, CD21 and CD22.
    [Show full text]
  • REVIEW Multiple Myeloma: the Cells of Origin – a Two-Way Street
    Leukemia (1998) 12, 121–127 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 REVIEW Multiple myeloma: the cells of origin – A two-way street JR Berenson, RA Vescio and J Said West Los Angeles VA Medical Center, UCLA School of Medicine, Los Angeles, CA, USA Multiple myeloma results from an interplay between the mono- earlier precursor cells may be responsible for the proliferation clonal malignant plasma cells and supporting nonmalignant of the malignant population. The presence of a circulating cells in the bone marrow. Recent studies suggest that the final transforming event in this B cell disorder occurs at a late stage tumor component without obvious plasma cell morphology of B cell differentiation based on the characteristics of the also suggests that less mature lymphocytes may be part of the immunoglobulin genes expressed by the malignant clone as clone as well, which could explain the dissemination of the well as surface markers present on the tumor cells. Recently, disease throughout the bone marrow.4 In addition, evidence an increasing pathogenic role in this malignancy by the nonma- for tumor cells at even earlier stages of hematopoietic differen- lignant cells in the bone marrow has been suggested by several tiation came from studies showing the high rate of acute non- studies. Specific infection of these supporting cells by the lymphoblastic leukemia in these patients and the presence of recently identified Kaposi’s sarcoma-associated herpes virus 5,6 (KSHV) suggests a novel mechanism by which this nonmalig- non-lymphoid surface markers on malignant plasma cells. A nant population may lead to the development of this B cell variety of molecular biological techniques have subsequently malignancy and support its growth.
    [Show full text]
  • Restoring Natural Killer Cell Immunity Against Multiple Myeloma in the Era of New Drugs
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Institutional Research Information System University of Turin Restoring Natural Killer Cell immunity against Multiple Myeloma in the era of New Drugs Gianfranco Pittari1, Luca Vago2,3, Moreno Festuccia4,5, Chiara Bonini6,7, Deena Mudawi1, Luisa Giaccone4,5 and Benedetto Bruno4,5* 1 Department of Medical Oncology, National Center for Cancer Care and Research, HMC, Doha, Qatar, 2 Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milano, Italy, 3 Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy, 4 Department of Oncology/Hematology, A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Torino, Italy, 5 Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy, 6 Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milano, Italy, 7 Vita-Salute San Raffaele University, Milano, Italy Transformed plasma cells in multiple myeloma (MM) are susceptible to natural killer (NK) cell-mediated killing via engagement of tumor ligands for NK activating receptors or “missing-self” recognition. Similar to other cancers, MM targets may elude NK cell immunosurveillance by reprogramming tumor microenvironment and editing cell surface antigen repertoire. Along disease continuum, these effects collectively result in a pro- gressive decline of NK cell immunity, a phenomenon increasingly recognized as a critical determinant of MM progression. In recent years, unprecedented efforts in drug devel- opment and experimental research have brought about emergence of novel therapeutic interventions with the potential to override MM-induced NK cell immunosuppression.
    [Show full text]
  • B-Cell Development, Activation, and Differentiation
    B-Cell Development, Activation, and Differentiation Sarah Holstein, MD, PhD Nov 13, 2014 Lymphoid tissues • Primary – Bone marrow – Thymus • Secondary – Lymph nodes – Spleen – Tonsils – Lymphoid tissue within GI and respiratory tracts Overview of B cell development • B cells are generated in the bone marrow • Takes 1-2 weeks to develop from hematopoietic stem cells to mature B cells • Sequence of expression of cell surface receptor and adhesion molecules which allows for differentiation of B cells, proliferation at various stages, and movement within the bone marrow microenvironment • Immature B cell leaves the bone marrow and undergoes further differentiation • Immune system must create a repertoire of receptors capable of recognizing a large array of antigens while at the same time eliminating self-reactive B cells Overview of B cell development • Early B cell development constitutes the steps that lead to B cell commitment and expression of surface immunoglobulin, production of mature B cells • Mature B cells leave the bone marrow and migrate to secondary lymphoid tissues • B cells then interact with exogenous antigen and/or T helper cells = antigen- dependent phase Overview of B cells Hematopoiesis • Hematopoietic stem cells (HSCs) source of all blood cells • Blood-forming cells first found in the yolk sac (primarily primitive rbc production) • HSCs arise in distal aorta ~3-4 weeks • HSCs migrate to the liver (primary site of hematopoiesis after 6 wks gestation) • Bone marrow hematopoiesis starts ~5 months of gestation Role of bone
    [Show full text]
  • Distribution in Trout Immune Tissues Plasmablast and Plasma Cell
    The Journal of Immunology Plasmablast and Plasma Cell Production and Distribution in Trout Immune Tissues1 Erin S. Bromage,* Ilsa M. Kaattari,* Patty Zwollo,† and Stephen L. Kaattari2* These studies describe the in vitro and ex vivo generation of plasmablasts and plasma cells in trout (Oncorhynchus mykiss) peripheral blood and splenic and anterior kidney tissues. Cells were derived either from naive trout and cultured with the polyclonal activator, Escherichia coli LPS, or from trout that had been immunized with trinitrophenyl-keyhole limpet hemocyanin. Hydroxyurea was used to resolve populations of replicating (plasmablast) and nonreplicating (plasma cell) Ab-secreting cells (ASC). Complete inhibition of Ig secretion was only observed within the PBL. Both anterior kidney and splenic lymphocytes possessed a subset of ASCs that were hydroxyurea resistant. Thus, in vitro production of plasma cells appears to be restricted to the latter two tissues, whereas peripheral blood is exclusively restricted to the production of plasmablasts. After immunization with trinitrophenyl-keyhole limpet hemocyanin, specific ASC could be isolated from all immune organs; however, the anterior kidney contained 98% of all ASC. Late in the response (>10 wk), anterior kidney ASC secreted specific Ab for at least 15 days in culture, indicating that they were long-lived plasma cells. Cells from spleen and peripheral blood lost all capacity to secrete specific Ab in the absence of Ag. Late in the Ab response, high serum titer levels are solely the result of Ig secretion from anterior kidney plasma cells. The Journal of Immunology, 2004, 173: 7317–7323. he immune system of the trout and other teleosts exhibits Plasma cells may become long-lived upon migration to a sup- two striking anatomical differences from mammals: 1) portive niche within the bone marrow, relying on specialized cues T they possess neither bone marrow nor lymph nodes; and for their longevity (14).
    [Show full text]
  • B Cell Responses: Plasmablasts Walk the Line
    RESEARCH HIGHLIGHTS B CELL RESPONSES Plasmablasts walk the line During an adaptive immune patterns in lymph nodes. Following molecule intercellular adhesion response, long-lived antibody- immunization with specific antigen, molecule 1 (ICAM1) in plasmablast producing plasma cells are generated YFP+ cells mainly aggregated in migration. Both YFP+ and naive in T cell-dependent germinal centres. the medulla of the lymph node but B cells migrated on ICAM1-coated Plasma cells subsequently localize to could also be found in the B and glass surfaces, but only naive B cells the lymph node medullary chords, T cell zones and at the border of required Gαi-signalling for this move- but their migration to these sites has germinal centres. By contrast, naive ment. In addition, naive B cells and never been directly observed. A study B cells were predominantly localized plasma blasts had different migratory in Immunity has now reported in B cell follicles. behaviour on the ICAM1-coated sur- unique migratory behaviour for their When the migratory patterns faces; naive B cells showed frequent precursors, plasmablasts; these cells of the different populations were detachment and reattachment to the traverse the lymph node in a linear observed in situ using time-lapse substrate, but YFP+ cells migrated in manner and, surprisingly, do not two-photon intravital microscopy, a steady, amoeboid manner. + require Gαi-coupled receptor YFP cells in the medullary chords Interestingly, in assays carried signalling to migrate. were found to be mainly stationary, out in vivo and in vitro, the authors The transcriptional repressor but YFP+ cells in the follicles were reported an inverse correlation B lymphocyte-induced maturation highly motile.
    [Show full text]
  • Lymphoid System IUSM – 2016
    Lab 14 – Lymphoid System IUSM – 2016 I. Introduction Lymphoid System II. Learning Objectives III. Keywords IV. Slides A. Thymus 1. General Structure 2. Cortex 3. Medulla B. Lymph Nodes 1. General Structures 2. Cortex 3. Paracortex 4. Medulla C. MALT 1. Tonsils 2. BALT 3. GALT a. Peyer’s patches b. Vermiform appendix D. Spleen 1. General Structure 2. White Pulp 3. Red Pulp V. Summary SEM of an activated macrophage. Lab 14 – Lymphoid System IUSM – 2016 I. Introduction Introduction II. Learning Objectives III. Keywords 1. The main function of the immune system is to protect the body against aberrancy: IV. Slides either foreign pathogens (e.g., bacteria, viruses, and parasites) or abnormal host cells (e.g., cancerous cells). A. Thymus 1. General Structure 2. The lymphoid system includes all cells, tissues, and organs in the body that contain 2. Cortex aggregates (accumulations) of lymphocytes (a category of leukocytes including B-cells, 3. Medulla T-cells, and natural-killer cells); while the functions of the different types of B. Lymph Nodes lymphocytes vary greatly, they generally all appear morphologically similar so cannot be 1. General Structures routinely distinguished in light microscopy. 2. Cortex 3. Lymphocytes can be found distributed throughout the lymphoid system as: (1) single 3. Paracortex cells, (2) isolated aggregates of cells, (3) distinct non-encapsulated lymphoid nodules in 4. Medulla loose CT associated with epithelium, or (4) encapsulated individual lymphoid organs. C. MALT 1. Tonsils 4. Primary lymphoid organs are sites where lymphocytes are formed and mature; they 2. BALT include the bone marrow (B-cells) and thymus (T-cells); secondary lymphoid organs are sites of lymphocyte monitoring and activation; they include lymph nodes, MALT, and 3.
    [Show full text]
  • IL-6 Supports the Generation of Human Long-Lived Plasma Cells in Combination with Either APRIL Or Stromal Cell-Soluble Factors
    Leukemia (2014) 28, 1647–1656 & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu ORIGINAL ARTICLE IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors M Jourdan1, M Cren1, N Robert2, K Bollore´ 2, T Fest3,4, C Duperray1,2, F Guilloton4, D Hose5,6,KTarte3,4 and B Klein1,2,7 The recent understanding of plasma cell (PC) biology has been obtained mainly from murine models. The current concept is that plasmablasts home to the BM and further differentiate into long-lived PCs (LLPCs). These LLPCs survive for months in contact with a complex niche comprising stromal cells (SCs) and hematopoietic cells, both producing recruitment and survival factors. Using a multi-step culture system, we show here the possibility to differentiate human memory B cells into LLPCs surviving for at least 4 months in vitro and producing immunoglobulins continuously. A remarkable feature is that IL-6 is mandatory to generate LLPCs in vitro together with either APRIL or soluble factors produced by SCs, unrelated to APRIL/BAFF, SDF-1, or IGF-1. These LLPCs are out of the cell cycle, express highly PC transcription factors and surface markers. This model shows a remarkable robustness of human LLPCs, which can survive and produce highly immunoglobulins for months in vitro without the contact with niche cells, providing the presence of a minimal cocktail of growth factors and nutrients. This model should be useful to understand further normal PC biology and its deregulation in premalignant or malignant PC disorders.
    [Show full text]
  • The Effects of Thymus and Other Lymphoid Organs Enclosed in Millipore Diffusion Chambers on Neonatally Thymectomized Mice* by David Osoba, M.D
    THE EFFECTS OF THYMUS AND OTHER LYMPHOID ORGANS ENCLOSED IN MILLIPORE DIFFUSION CHAMBERS ON NEONATALLY THYMECTOMIZED MICE* BY DAVID OSOBA, M.D. (From the Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada) PLATES 39 XO 42 (Received for publication, April 7, 1965) The possibility that the thymus produces a humoral substance with far reaching biological effects has been frequently considered. Support for the production of a hormone has been offered on morphological grounds by the description of secretory vesicles in the frog thymus (1), and colloid-containing cysts lined by ciliated cuboidal cells in normal mouse thymus (2, 3). Although there have been claims of the discovery of thymus-derived substances exhibiting anticancer properties (4, 5), with growth-promoting or growth-retarding effects (6), and with antibacterial (7) and antiviral activity (8), none of these claims has been widely substantiated. Meanwhile, the possibility that the thymus, e/a a humoral factor, exerts an effect on other lymphoid tissue has been receiving increasing support. Several authors have reported a transient lymphocytosis-stimulating effect following the injection of a variety of thymus extracts in guinea pigs (9) and mice thymec- tomized in adult life (10), in intact neonatal mice (11), and in young rabbits (12) and rats (13). Also, extracts and implants of heavily irradiated thymuses from pigs and rabbits have been found to produce a lymphoid hyperplastic response in the regional lymph nodes of young rats (14). Direct evidence that the thymus produces a humoral factor, which plays a role in the development of immunity, has been provided by the discovery that the deficient immune responses found in mice after neonatal thymectomy can be prevented by intraperitoneally implanted grafts of thymus tissue enclosed within Millipore diffusion chambers (15-19).
    [Show full text]
  • Antigens Cell-Independent Or T Cell-Dependent Induced Early In
    Long-Lived Bone Marrow Plasma Cells Are Induced Early in Response to T Cell-Independent or T Cell-Dependent Antigens This information is current as of October 2, 2021. Alexandra Bortnick, Irene Chernova, William J. Quinn III, Monica Mugnier, Michael P. Cancro and David Allman J Immunol 2012; 188:5389-5396; Prepublished online 23 April 2012; doi: 10.4049/jimmunol.1102808 Downloaded from http://www.jimmunol.org/content/188/11/5389 Supplementary http://www.jimmunol.org/content/suppl/2012/04/24/jimmunol.110280 Material 8.DC1 http://www.jimmunol.org/ References This article cites 48 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/188/11/5389.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on October 2, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Long-Lived Bone Marrow Plasma Cells Are Induced Early in Response to T Cell-Independent or T Cell-Dependent Antigens Alexandra Bortnick,* Irene Chernova,* William J.
    [Show full text]
  • The Bone Marrow As Sanctuary for Plasma Cells and Memory T-Cells: Implications for Adaptive Immunity and Vaccinology
    cells Review The Bone Marrow as Sanctuary for Plasma Cells and Memory T-Cells: Implications for Adaptive Immunity and Vaccinology Stefan A. Slamanig 1,2,† and Martijn A. Nolte 1,2,* 1 Department of Molecular Hematology, Sanquin Research, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands; [email protected] 2 Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands * Correspondence: [email protected] † Current address: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Abstract: The bone marrow (BM) is key to protective immunological memory because it harbors a major fraction of the body’s plasma cells, memory CD4+ and memory CD8+ T-cells. Despite its paramount significance for the human immune system, many aspects of how the BM enables decade-long immunity against pathogens are still poorly understood. In this review, we discuss the relationship between BM survival niches and long-lasting humoral immunity, how intrinsic and extrinsic factors define memory cell longevity and show that the BM is also capable of adopting many responsibilities of a secondary lymphoid organ. Additionally, with more and more data on the differentiation and maintenance of memory T-cells and plasma cells upon vaccination in humans being reported, we discuss what factors determine the establishment of long-lasting immunological memory in the BM and what we can learn for vaccination technologies and antigen design. Finally, using these insights, we touch on how this holistic understanding of the BM is necessary for the development of modern and efficient vaccines against the pandemic SARS-CoV-2. Citation: Slamanig, S.A.; Nolte, M.A.
    [Show full text]
  • Single-Cell Sequencing Reveals Clonally Expanded Plasma Cells During Chronic Viral Infection Produce Virus-Specific and Cross-Reactive Antibodies
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.29.428852; this version posted January 31, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Single-cell sequencing reveals clonally expanded plasma cells during chronic viral infection produce virus-specific and cross-reactive antibodies Daniel Neumeier1, Alessandro Pedrioli2 , Alessandro Genovese2, Ioana Sandu2, Roy Ehling1, Kai-Lin Hong1, Chrysa Papadopoulou1, Andreas Agrafiotis1, Raphael Kuhn1, Damiano Robbiani1, Jiami Han1, Laura Hauri1, Lucia Csepregi1, Victor Greiff3, Doron Merkler4,5, Sai T. Reddy1,*, Annette Oxenius2,*, Alexander Yermanos1,2,4,* 1Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland 2Institute of Microbiology, ETH Zurich, Zurich, Switzerland 3Department of Immunology, University of Oslo, Oslo, Norway 4Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland 5Division of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland *Correspondence: [email protected] ; [email protected] ; [email protected] Graphical abstract. Single-cell sequencing reveals clonally expanded plasma cells during chronic viral infection produce virus-specific and cross-reactive antibodies. bioRxiv preprint doi: https://doi.org/10.1101/2021.01.29.428852; this version posted January 31, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Neumeier et al., Abstract Plasma cells and their secreted antibodies play a central role in the long-term protection against chronic viral infection.
    [Show full text]